Last reviewed · How we verify
NCT05238532
Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of CT303 in Patients With ARDS
Phase 1 trial testing CT303 in Acute Respiratory Distress Syndrome. Withdrawn.
22 February 2023
Quick facts
| Lead sponsor | GC Cell Corporation |
|---|---|
| Phase | Phase 1 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Start date | 26 January 2022 |
| Primary completion | 22 February 2023 |
| Estimated completion | 22 February 2023 |
| Sites | 3 locations across South Korea |
Drugs / interventions tested
- CT303
Conditions studied
- Acute Respiratory Distress Syndrome — all drugs for Acute Respiratory Distress Syndrome →
Sponsor
GC Cell Corporation — full company profile →
Who can join
19 and older, any sex, with Acute Respiratory Distress Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Evaluate the safety, tolerability, efficacy and pharmacodynamics\&pharmacokinetic properties of CT303 in patients with ARDS.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05238532
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of CT303
Trials testing the same drug.
- NCT05258331 — Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of CT303 in Patients With Psoriasis · Phase 1 · unknown
Other recruiting trials for Acute Respiratory Distress Syndrome
Currently open trials in the same condition.
- NCT07284888 — Practices of Prone Positioning Ventilation in Patients With Moderate-to-Severe ARDS in Intensive Care Units: A Registry- · recruiting
- NCT07289711 — Validation and Precision Treatment of Inflammatory Subphenotypes in Acute Respiratory Distress Syndrome: A Multicenter C · recruiting
- NCT07326215 — A Study of the Efficacy and Safety of Extracorporeal Carbon Dioxide Removal Using PrismaLung+ · NA · recruiting
- NCT06919484 — The Physiological Effect of RCexp on Ventilation/Perfusion Distribution · recruiting
- NCT07126964 — Extended Prone Positioning for Intubated ARDS · NA · recruiting
Other GC Cell Corporation trials
Trials by the same sponsor.
- NCT06620510 — Retrospective Study of Long-Term Survival of "Immuncell-LC" in Patients Undergoing Curative Resection for HCC in Korea · completed
- NCT05258331 — Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of CT303 in Patients With Psoriasis · Phase 1 · unknown
- NCT03983967 — Evaluate the Efficacy and Safety of 'Immuncell-LC' in Patients Undergoing Liver Transplantation · Phase 1, PHASE2 · completed
- NCT03778619 — MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin · Phase 1, PHASE2 · unknown
- NCT02856815 — Safety and Efficacy of "Immuncell-LC" in TACE Therapy · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05238532 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by GC Cell Corporation
- Last refreshed: 4 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05238532.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing